2006
Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection
Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection. The Journal Of Infectious Diseases 2006, 193: 1375-1383. PMID: 16619185, DOI: 10.1086/503371.Peer-Reviewed Original ResearchConceptsTreatment failureMeglumine antimoniatePrimary resistanceAntimonial drugsSecondary resistanceDrug resistanceHuman Leishmania infectionsEffective immune responseAnthroponotic visceral leishmaniasisAmerican cutaneous leishmaniasisAntimonial therapyStandard treatmentCutaneous diseaseLeishmania infectionTherapeutic responseImmune responseCutaneous leishmaniasisVisceral leishmaniasisAnthroponotic transmissionResistant organismsEffective doseIntracellular amastigotesSusceptible strainsAntimoniatePatients
1998
Sensitivity of Leishmania viannia panamensis to Pentavalent Antimony Is Correlated with the Formation of Cleavable DNA-Protein Complexes
Lucumi A, Robledo S, Gama V, Saravia N. Sensitivity of Leishmania viannia panamensis to Pentavalent Antimony Is Correlated with the Formation of Cleavable DNA-Protein Complexes. Antimicrobial Agents And Chemotherapy 1998, 42: 1990-1995. PMID: 9687395, PMCID: PMC105721, DOI: 10.1128/aac.42.8.1990.Peer-Reviewed Original ResearchConceptsSbv/Sodium stibogluconateAntimonial drugsHuman promonocytic cell line UCleavable complexLeishmania Viannia panamensisAntimonial agentsMedian ED50Meglumine antimoniateCell line UEffective doseEffects of camptothecinPentavalent antimonyPromastigotes of LeishmaniaReports of inhibitionInhibitors of topoisomeraseInhibition of topoisomeraseLeishmania donovaniL. panamensisLeishmaniaAntimoniatePatientsRelapseStibogluconateLine U